Cargando…

Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours

ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generall...

Descripción completa

Detalles Bibliográficos
Autores principales: Legrand, Arnaud J., Choul-li, Souhaila, Villeret, Vincent, Aumercier, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487777/
https://www.ncbi.nlm.nih.gov/pubmed/37686260
http://dx.doi.org/10.3390/ijms241713454
_version_ 1785103321476890624
author Legrand, Arnaud J.
Choul-li, Souhaila
Villeret, Vincent
Aumercier, Marc
author_facet Legrand, Arnaud J.
Choul-li, Souhaila
Villeret, Vincent
Aumercier, Marc
author_sort Legrand, Arnaud J.
collection PubMed
description ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications.
format Online
Article
Text
id pubmed-10487777
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104877772023-09-09 Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours Legrand, Arnaud J. Choul-li, Souhaila Villeret, Vincent Aumercier, Marc Int J Mol Sci Review ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications. MDPI 2023-08-30 /pmc/articles/PMC10487777/ /pubmed/37686260 http://dx.doi.org/10.3390/ijms241713454 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Legrand, Arnaud J.
Choul-li, Souhaila
Villeret, Vincent
Aumercier, Marc
Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
title Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
title_full Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
title_fullStr Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
title_full_unstemmed Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
title_short Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
title_sort poly(adp-ribose) polyremase-1 (parp-1) inhibition: a promising therapeutic strategy for ets-expressing tumours
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487777/
https://www.ncbi.nlm.nih.gov/pubmed/37686260
http://dx.doi.org/10.3390/ijms241713454
work_keys_str_mv AT legrandarnaudj polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours
AT choullisouhaila polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours
AT villeretvincent polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours
AT aumerciermarc polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours